Abstract: Objective：To investigate the efficacy and safety of apatinib with non-interfered in patients with EGFR gene wild type or unknown of advanced non-small cell lung cancer(NSCLC)， and explore the possible related factors of the effect.Methods：All the patients come from our hospital which is chemotherapy-faild advanced NSCLC of EGFR genes wild type or unknown from August 2015 to April 2017.All the patients received apatinib 425 mg once daily orally in 4-weeks cycle and adverse events were followed up.The end point was progress free survival(PFS)， objective response rate(ORR)，disease control rate(DCR).Results：Thirty-four patients were enrolled，of which the efficacy can be evaluated in 30 patients while the other 4 can not because of severe adverse events. The total median PFS was 3.75months（95%CI：0.648~6.852）.The number of response were： partial remission(PR) 6 cases(20.00%)， stead disease(SD) 16 cases(53.33%)， progress disease(PD) 7 cases (23.33%). The overall response rate(ORR) and the disease control rate(DCR) were 20%，73.33% respectively.The most frequently observed adverse event were 18 cases hypertension(52.94%)， 18 cases hand-foot syndrome(52.94%)， 15 cases proteinuria(44.12%)， and 14 cases fatigue(41.18%). No medicine-related death were found. Correlation analysis showed ECOG 0~1 and combination chemotherapy were two affecting factors of PFS，and the latteris independent predictor.Conclusion：The treatment of chemotherapy-faild advanced non-small lung cancer with apatinib have better exact affect， and toxicity could be controlled.So it has certain value of clinical application or large-scale clinical research.